AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Abilify (aripiprazole) approved for marketing in Europe for the treatment of schizophrenia.
(From Chemical Business NewsBase - Press Release)
Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co Ltd (Otsuka) announced that the European Commission has granted marketing authorisation for Abilify (aripiprazole), an antipsychotic medication, for the treatment of schizophrenia. Receiving marketing approval for Abilify in 25 nations of the European Union marks a significant milestone for Abilify and for both companies. Otsuka Pharmaceutical Europe Ltd, the London subsidiary of Otsuka Pharmaceutical Co Ltd, holds the marketing authorisation for Abilify in Europe. Bristol-Myers Squibb and Otsuka will co-promote Abilify in several European countries. The efficacy of ...
- Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Submit New Drug...
- Press release article from: PR Newswire November 7, 2001 700+ words
...these data, Bristol-Myers Squibb and Otsuka Pharmaceutical also expect to file...About Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., are...
- Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify to Garner 12% of the...
- Press release article from: PR Newswire June 16, 2003 700+ words
...leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify will garner 12% of the schizophrenia market in 2012 when it emerges as a first-choice...
- Otsuka licenses domestic rights to B-MS' saxagliptin.(Otsuka...
- Newspaper article from: Pharma Marketletter January 8, 2007 700+ words
Japan's Otsuka Pharmaceutical has been granted exclusive domestic rights to develop and commercialize US drug major Bristol-Myers Squibb's investigational compound saxagliptin, for the treatment of type 2 diabetes. Otsuka gains rights to...
- Otsuka Pharmaceutical and Bristol-Myers Squibb announced that the FDA approved...
- Magazine article from: Medical Marketing & Media December 1, 2007 700+ words
Otsuka Pharmaceutical and Bristol-Myers Squibb announced that the FDA approved the supplemental NDA for the atypical antipsychotic Abilify (aripiprazole) for the treatment...
- Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive...
- Press release article from: PR Newswire December 27, 2006 700+ words
...FirstCall/ -- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today...About Bristol-Myers Squibb Bristol-Myers Squibb is a global pharmaceutical...human life. About Otsuka Pharmaceutical Co., Ltd. Founded...
- Abilify wins clearance.(RX: RETAIL PHARMACY: Branded Drugs)(FDA approves...
- Magazine article from: Chain Drug Review March 17, 2008 700+ words
The FDA has approved Abilify for the treatment of acute bipolar I disorder in patients between ages 10 and 17. The product is marketed by Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Co.
- FDA clears new indication for Abilify.(Otsuka Pharmaceutical Company Ltd. and...
- Newspaper article from: Pharma Marketletter March 21, 2005 700+ words
Tokyo, Japan-based Otsuka Pharmaceutical and the USA's Bristol-Myers Squibb say that the US Food and Drug Administration has approved a new use for their antipsychotic Abilify (ariprazole). The agent...
- Bristol-Myers Squibb and Otsuka Pharmaceutical Spend Nearly Twice as Much on...
- Press release article from: PR Newswire March 5, 2008 700+ words
...a new report that finds that Bristol-Myers Squibb and Otsuka Pharmaceutical spend almost twice as much on Abilify...and fewer than 10% mention Bristol- Myers Squibb or Otsuka Pharmaceutical as a top-of-mind company in atypical...